semaglutide select Full Results Affirm CV Risk Reduction With in Nondiabetics SELECT trial shows cardiovascular risk

It should not be confused with Rybelsus, a lower-dose oral semaglutide licensed only for type 2 diabetes

10.1016/S0070-2137(96)80007-0 Curr

Methods We used Mendelian randomization to obtain unconfounded estimates

You may be a potential candidate if you: Have a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with a weight-related condition such as high blood pressure or high cholesterol Have experienced ongoing weight gain and limited progress alone Have weight-related health concerns and are seeking medically guided support Prefer an online evaluation process and are unable to attend frequent in-person appointments Disclaimer: Medical weight loss programs are not appropriate for everyone

GLP-1 is a useful therapeutic modulator of depression, suggesting that abnormal alteration of neurotransmitter levels in the depressive brain results in mood impairment and cognitive decline

If you or a loved one are on Medicare and curious about access to GLP-1 medications for obesity treatment, this episode explains the key timelines, eligibility criteria, and practical steps patients should take with their doctors